AER 003, a PEGylated IL-4/IL-13 Antagonist, Significantly Reduces Allergen-Induced Airway Hyperresponsiveness (AHR)

A double-blind, randomized, two-period cross-over study investigated the effect of a single subcutaneous dose of AER 003 or placebo administered on Day 1, on allergen-induced AHR and airway eosinophilia in the Cynomolgus monkey.

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 125; no. 2; p. AB54
Main Authors Tomkinson, A, Stevens, L, Morton, M, Bowden, A, Wong, T, Boisvert, D, Delaria, K, Getz, E. Burmeister
Format Journal Article
LanguageEnglish
Published St. Louis Mosby, Inc 01.02.2010
Elsevier Limited
Subjects
Allergy and Immunology
Asthma
Online AccessGet full text

Cover

More Information
Summary:A double-blind, randomized, two-period cross-over study investigated the effect of a single subcutaneous dose of AER 003 or placebo administered on Day 1, on allergen-induced AHR and airway eosinophilia in the Cynomolgus monkey.
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2009.12.246